Organization · Venture Capital
Longwood Fund
Longwood Fund is a Boston-based venture capital firm that creates and invests in science-based healthcare companies addressing significant medical needs. The firm is known for its hands-on approach, actively co-founding companies and often taking on executive roles.
Overview
What Longwood Fund does
What Longwood Fund is
Longwood Fund is a Boston-based venture capital firm that creates and invests in science-based healthcare companies addressing significant medical needs. The firm is known for its hands-on approach, actively co-founding companies and often taking on executive roles.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2010
- Approximate age
- About 16 years
- Structured capabilities
- Funder
- Last reviewed
- March 26, 2026
Official channels
Find Longwood Fund elsewhere
Open the official website or a supported primary organization account.
Capability profile
Longwood Fund as a funder
Investment thesis
Longwood Fund focuses on creating and investing in innovative healthcare companies that address significant medical needs through science-based therapies.
Focus narrative
Longwood Fund invests in science-based companies that tackle significant medical challenges. The firm collaborates with world-class entrepreneurs and academic innovators to identify and develop groundbreaking discoveries in healthcare, particularly in oncology, neurology, and rare genetic diseases.
Value beyond capital
Longwood Fund adds value to its portfolio companies by actively participating in their creation and development. Partners often take on executive roles within the companies, providing strategic guidance and operational support. This hands-on approach, combined with their extensive network in the biotech industry, enhances the potential for success and accelerates the path to market for innovative therapies.
Terms and economics
- Typical check
- $100,000–$5,000,000
- Sweet spot
- $1,500,000
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series A+
- Sectors
- Biotech · Healthcare · Cell Gene Therapy
- Regions
- North AmericaUnited States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded notable exits
- Grail, Alnylam Pharmaceuticals, Vertex Pharmaceuticals, Acceleron Pharma, Momenta Pharmaceuticals, and Sirtris Pharmaceuticals
Portfolio context
Notable portfolio companies include: Immunitas Therapeutics: Utilizes a single-cell genomics platform to advance discoveries in immune cell biology for clinical improvements. Be Biopharma: Develops engineered B cells as a new category of cellular medicines. Interius BioTherapeutics: A preclinical stage gene therapy company focused on in vivo cell-specific gene delivery. Rectify Pharma: Works on developing disease-modifying precision therapeutics for serious genetic diseases. AAVantgarde Bio: Focuses on delivering next-generation gene therapies.
Common questions
What to know about Longwood Fund
Upseed classifies Longwood Fund under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.